Arranta Bio is a contract development and manufacturing organization (CDMO) specifically established to focus on serving companies seeking to develop and commercialize therapies targeting the human microbiome.
Headed by a management team and technical experts with a proven track record, we offer the knowledge and resources necessary to help you to develop and manufacture promising new microbiome-based therapies to meet the needs of patients.
Aaron Cowley and partners launched Captozyme in 2009. Inspired by various influences and most notably by a speech from a mother who had lost a child to a rare disease, they were driven to start the business with the passion that their efforts could result in significant change. Growing the business with a team of talented individuals dedicated to manufacturing live biotherapeutics, Captozyme merged with Arranta Bio in November 2019. The products business of Captozyme was separately spun out under the control of the former CEO.
Captozyme’s legacy facility in Gainesville, Florida continues to serve clients as Arranta Bio’s Center of Excellence for process development and early clinical supply, staffed by its experienced team under the leadership of Aaron Cowley, Chief Scientific Officer. Arranta Bio is expanding the Gainesville facility with additional PD and QC labs, and a second GMP manufacturing line.Read The Full Press Release
Mark R. Bamforth
Founder, President & CEO
independent Board Director
Chief Scientific Officer
Chief Operations Officer
Chief Financial Officer
Chief Legal Officer & General Counsel
Vice President of Information Technology
Vice President, Quality and Regulatory